At MechanoNexus, we develop cutting-edge treatments for orthopedic conditions, focusing on bone regeneration and repair. By harnessing mechanotransduction and advanced stem cell therapies, we create innovative solutions that enhance the body’s natural healing processes.
Our first breakthrough treatment, Prosopomech, targets fracture repair in individuals with osteogenesis imperfecta (OI), utilising periosteal stem cells engineered for increased mechanoresponsiveness. As we grow, we aim to expand our technology to address a wider range of bone fragility disorders, non-union fractures, and post-surgical bone healing challenges.
1. Significant mechanosensitivity of activated stem cells
2. Successful integration into controlled fracture models
3. Surpasses existing treatments by significantly increasing bone tissue density, volume, and mechanical strength
4. Specific upregulation of collagen fibril formation
5. Stimulates accelerated fracture repair through enhanced cellular coordination and tissue remodelling
6. Safeguards against future fractures by improving bone architecture and biomechanical resilience
“At MechanoNexus, we’ve built an exceptional foundation of scientific expertise through years of dedicated work in biological sciences. Our passion lies in turning that knowledge into real-world solutions for some of the most challenging medical conditions.
Right now, our sights are set on Osteogenesis Imperfecta – a rare and often overlooked disease. Armed with a comprehensive understanding of bone biology and regeneration, we’re determined to push boundaries and bring meaningful change to the lives of those affected.”
Chief Medical Officer
Patent Lawyer and Marketing Director
Production Manager
Medical Director
